Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 11, 2015, Pages 1379-1391

  Borody, Thomas ^a   Fischer, Monika ^b   Mitchell, Scott ^a   Campbell, Jordana ^a  

^a Centre for Digestive Diseases   (Australia)

^b INDIANA UNIVERSITY   (United States)

Author keywords

antibiotic resistance; fecal microbiota transplantation; FMT; FSM; full spectrum microbiota; microbiome; probiotics

Indexed keywords

FECAL MICROBIOTA TRANSPLANTATION PRODUCT; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO; PROBIOTIC AGENT; RBX 2660; SER 109; UNCLASSIFIED DRUG;

CLOSTRIDIUM DIFFICILE INFECTION; DONOR; ENCAPSULATION; EPIDEMIC; FECAL MICROBIOTA TRANSPLANTATION; FREEZE DRYING; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; INTESTINE FLORA; MEDICAL PROCEDURES; MICROBIOME; MORTALITY; POWDER; REVIEW; TREATMENT INDICATION; UNITED STATES; ADVERSE EFFECTS; ANIMAL; FECES; FORECASTING; GASTROINTESTINAL DISEASES; INTESTINE; MASS COMMUNICATION; MICROBIOLOGY; TREATMENT OUTCOME; TRENDS;

ANIMALS; DIFFUSION OF INNOVATION; FECAL MICROBIOTA TRANSPLANTATION; FECES; FORECASTING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; TREATMENT OUTCOME;

EID: 84947125813     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1086267     Document Type: Review

References (91)

1. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimen Pharmacol Therap 2015; 41 (9): 835-43
2. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108 (4): 500-8
3. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368 (5): 407-15
4. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Infec Dis Soc Am 2014; 58 (11): 1515-22
5. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (4): 478-98; quiz 499
6. Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Infec Dis 2014; 20 (Suppl 2): 1-26
7. Moayyedi P, Marshall JK, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J gastroenterol hepatol 2014; 28 (2): 66-8
8. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48 (8): 693-702
9. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: »first-line» treatment for severe clostridium difficile infection? J Clin Gastroenterol 2011; 45 (8): 655-7
10. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44 (5): 854-9
11. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Therapeut 2015; 42 (4): 470-6
12. Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. J Transplan Soc 2012; 14 (6): E161-5
13. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 2013; 47 (8): 735-7
14. You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008; 148 (8): 632-3
15. Zainah H, Hassan M, Shiekh-Sroujieh L, et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci 2015; 60 (1): 181-5
16. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11 (8): 1036-8
17. FDA. Guidance for industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. FDA Center for Biologics and Research Marlyand, USA. FDA, 2013. Available at http://www.fda.gov/downloads/BiologicsBloodVaccinesGuidanceComplianceRegulatoryInformationGuidancesVaccinesUCM387255.pdf
18. Olefson SH, Jackson M, Kelly C. Clostridium difficile: The Spectrum of Diagnoses in Patients Referred for Fecal Microbiota Transplant. Gastroenterology 2015; 148 (4): S727
19. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. J Am Gastroenterol Assoc 2011; 9 (12): 1044-9
20. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107 (5): 761-7
21. Smith MB, Kassam Z, Burgess J, et al. The international public stool bank: a scalable model for standardized screening and processing of donor stool for fecal microbiota transplantation. Gastroenterology 2015; 148 (4): S-211
22. Paramsothy S, Borody T, Lin E, et al. Obstacles to Donor Recruitment for Faecal Microbiota Transplantation: Experiences From the FOCUS Study. Am J Gastroenterol 2014; S188
23. Burns LJ, Dubois N, Smith MB, et al. Donor Recruitment and Eligibility for Fecal Microbiota Transplantation: Results From an International Public Stool Bank. Gastroenterology 2015; 148 (4): S-96-7
24. Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. J Am Gastroenterol Assoc 2014; 12 (9): 1572-6
25. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. J Ame Med Assoc 2014; 312 (17): 1772-8
26. Stollman N, Smith M, Giovanelli A, et al. Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. Am J Gastroenterol 2015; 110 (4): 600-1
27. Hirsch BE, Saraiya N, Poeth K, et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015; 15 (1): 191
28. Lin E, Furnari V, Wong C, et al. Twelve Week Storage Trial of Microbial Viability in Lyophilized and Frozen Fecal Microbiota Preparations. Gastroenterology 2015; 148 (4): S962
29. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Infec Dis Soc Am 2011; 53 (10): 994-1002
30. Konijeti GG, Sauk J, Shrime MG, et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Infec Dis Soc Am 2014; 58 (11): 1507-14
31. Byrn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008; 143 (2): 150-4; discussion 155
32. Chan S, Kelly M, Helme S, et al. Outcomes following colectomy for Clostridium difficile colitis. Int J Surg 2009; 7 (1): 78-81
33. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Gastroenterol 2012; 5 (6): 403-20
34. van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol 2014; 30 (1): 34-9
35. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortaility, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am 2015; 29 (1): 123-4
36. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7 (7): 526-36
37. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nature reviews. Gastroenterol hepatol 2012; 9 (2): 88-96
38. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emer Infect Dis 2006; 12 (3): 409-15
39. Jump RL. Clostridium difficile infection in older adults. Aging health 2013; 9 (4): 403-14
40. Agrawal M, Aroniadis OC, Brandt LJ, et al. A Long-Term Follow-Up Study of the Efficacy and Safety of Fecal Microbiota Transplant (FMT) for Recurrent/Severe/Complicated C. difficile Infection (CDI) in the Elderly. Gastroenterol 2014; 146 (5): S-42-3
41. de Castro CG Jr, Ganc AJ, Ganc RL, et al. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant 2015; 50 (1): 145
42. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infec 2015; 21 (4): 230-7
43. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109 (7): 1065-71
44. Brandt L, Aroniadis O, Greenberg A, et al. Safety of fecal microbiota transplantation (FMT) in immunocompromised (IC) patients with inflammatory bowel disease (IBD). Am J Gastroenterol 2013; 108
45. Costello SP, Chung A, Andrews JM, Fraser RJ. Fecal Microbiota Transplant for Clostridium difficile Colitis-Induced Toxic Megacolon. Am J Gastroenterol 2015; 110 (5): 775-7
46. Gweon TG, Lee KJ, Kang DH, et al. A case of toxic megacolon caused by clostridium difficile infection and treated with fecal microbiota transplantation. Gut and liver 2015; 9 (2): 247-50
47. Stein D, Rizvi S, Modiri AN, et al. Two case reports of toxic megacolon from Clostridium difficile infection successfully treated with fecal microbiota therapy. Gastroenterology 2015; 148 (4): S645
48. Yu S, Abdelkarim A, Nawras A, et al. Fecal transplant for treatment of toxic megacolon associated with clostridium difficile colitis in a patient with duchenne muscular dystrophy. Am J Ther 2014. [Epub ahead of print]
49. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347 (6): 417-29
50. Cammarota G, Ianiro G, Cianci R, et al. The involvement of inflammatory bowel disease pathogenesis: potential for therapy. Pharmacology and therapeutics 2015; 149: 191-212
51. Sasaki M, Klapproth JM. The role of bacteria in the pathogenesis of ulcerative colitis. J Signal Transduct 2012; 2012: 704953
52. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122 (1): 44-54
53. Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Exp Rev Gastroenterol Hepatol 2011; 5 (6): 653-5
54. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1 (8630): 164
55. Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149 (1): 102-9; e106
56. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149 (1): 110-18; e114
57. Meyer AM, Ramzan MD, Loftus EV, et al. The diagnostic yield of stool pathogen studies of inflammatory bowel disease. J Clin Gastroenterol 2004; 38 (9): 772-5
58. Jen MH, Saxena A, Bottle A, et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Alimen Pharmacol Therapeut 2011; 33 (12): 1322-31
59. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57 (2): 205-10
60. Borody T, Torres M, Campbell J, et al. Reversal of inflammatory bowel disease (IBD) with recurrent faecal microbiota transplants (FMT). Am J gastroenterol 2011; 106: S366
61. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns & colitis 2014; 8 (12): 1569-81
62. Singh R, van Nood E, Nieuwdorp M, et al. Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. Europ Soc Clin Micro Infec Dis 2014; 20 (11): O977-8
63. Freedman A. Use of stool transplant to clear fecal colonization with carbapenem-resistant enterobacteraciae (CRE): Proof of concept. In: Infectious Diseases Society of America. Philadelphia, PA, USA, 2014
64. Dubberke E, Jones C. Clearance of vancomycin-resistant enterococcus concomitant with administration of a microbiota-based drug targeted at recurrent clostridium difficile infection. In: 25th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, 2014
65. Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 2015; 53 (6): 1986-9
66. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? J Europ Gastrointes Mot Soc 2015; 27 (1): 19-29
67. Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointes Liver physiol 2013; 305 (8): G529-41
68. Pinn DM, Aroniadis O, Brandt LJ. Long-term follow-up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS). Am J gastroenterol 2013; 108 (Suppl 1s): S1862
69. Addamo CJ, Birath S, McCoy A, et al. Gut Bacteria and Inflammation Are Associated With Diverticulosis. Gastroenterology 2011; 148 (4): S-731
70. Ananthaswamy A. Faecal transplant eases symptoms of Parkinsons disease. New Sci 2011; 209 (2796): 8-9
71. Borody T, Nowak A, Torres M, et al. Bacteriotherapy in Chronic Fatigue Syndrome (CFS): A Retrospective Review. Am J gastroenterol 2012; S591
72. Borody T, Leis S, Campbell J, et al. Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS). Am J Gastroenterol 2011; 106: P352
73. Borody T, Rosen DM, Torres M, et al. Myoclonus-dystonia (M-D) mediated by GI microbiota diarrhoea treatment improves M-D symptoms. Am J Gastroenterol 2011; 106: S352
74. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014; 146 (6): 1525-33
75. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143 (4): 913-16; e917
76. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013; 15 (8): 337
77. Hudy L, Manichanh C, Santiago A, et al. Phase I trial on FMT in autistic children. In: 5th International Human Microbiome Congress. Luxembourg, 2015
78. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013; 78 (2): 240-9
79. New ways to treat challenging diseases. Available from: www.rebiotix.com/
80. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1 (8648): 1156-60
81. Nash A, Wong MC, Hyde E, et al. Triple species cocktail for treatment of recurrent C. difficile infection. In: Freston Conference. Chicago, Illinois, 2014
82. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: RePOOPulating the gut. Microbiome 2013; 1 (1): 3
83. Jorup-Ronstrom C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012; 47 (5): 548-52
84. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473 (7346): 174-80
85. Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44 (8): 551-61
86. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001; 73 (2 Suppl): 399S-405S
87. Kahn SA, Gorawara-Bhat R, Rubin DT. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis 2012; 18 (4): 676-84
88. Khanna S, Pardi DS, Kelly C, et al. Clinical evaluation of SER-109, a rationally designed, oral microbiome-based therapeutic for the treatment of recurrent clostridium difficile. Gastroenterology 2014; 149 (1): 223-37
89. FDA. FDA Investigates presence of mucormycosis-causing mold in infant and childrens probiotic supplement FDA Recalls, outbreaks and emergencies. Maryland, USA. FDA, 2014. Available at http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm423830.htm
90. Chaudhry R, Dhawan B, Kumar D, et al. Outbreak of suspected Clostridium butyricum botulism in India. Emerg Infect Dis 1998; 4 (3): 506-507
91. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Infec Dis Soc Am 2005; 41 (11): 1559-68